Nanergy Inc. to Brief Shareholders on Product Plans; Dr. Kiss to Host Investor Conference Call on 8/15 at 12:00 pm EDT 8/10/2005 7:30:03 AM
NEW YORK, Aug 10, 2005 (BUSINESS WIRE) -- Nanergy Inc. ("Nanergy") (OTC Other: NNGY), today announced that Dr. Zoltan Kiss, who will become President effective Sept. 1, will brief investors on Nanergy's product development plans, patent status, schedule for availability of production prototypes, initial production, marketing thrust and financing during a call-in investor conference to be held on August 15th, at 12:00 EDT.
To access the conference, please dial 866-295-5950 and enter participant passcode 71056#. A recorded version of the conference will be posted on the Company's website at www.nanergyinc.com as soon as possible after the conference.
Management plans to conduct shareholder teleconferences on a regular basis update shareholders and potential investors.
About Nanergy Inc.
Nanergy Inc. is a developmental stage company headquartered in New York City, with offices near Princeton, NJ at 4260 Rt 1, Suite 7, Monmouth Junction, NJ 08852 (Tel 732 329-0045) as well as in Hungary. Its focus is on developing exciting consumer products that harness nanotechnology, and especially photovoltaic nanofilms, while conducting ongoing research in storing hydrogen using carbon nanotubes. Its new corporate website is still being developed but is available for viewing at http://www.nanergyinc.com.
SOURCE: Nanergy Inc. DeMonte Associates Investors: Cynthia DeMonte, 212-605-0525 cdemonte@aol.com www.demonte.com .
Posted by YellowSubmarine on :
News: NanoViricides Announces Progress in Development of FluCide-I Influenza Drug 'Bird Flu Drug Meeting in Vietnam Planned for December as International Concern Is Mounting that the Disease Could Mutate into a Major Killer' 9/20/2005 3:52:57 PM NEW YORK, Sept. 20, 2005, Sep 20, 2005 (PRIMEZONE via COMTEX) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced today that the Company is actively developing its first NanoViricide(tm) drug, "FluCide-I(tm)." The Company expects to commence studies in external laboratories within a matter of weeks to verify the drug's effectiveness and basic safety profile against the influenza virus. Animal studies as well as cell culture studies will be initiated.
The Company has accelerated its development of FluCide-I in order to have basic safety and efficacy data on the anti-influenza system when it meets in December with the Government of Vietnam's National Institute of Hygiene and Epidemiology ("NIHE"). NIHE is Vietnam's leading institute for the surveillance, control and prevention of infectious diseases. They have extended an invitation to the Company to discuss the use of the NanoViricide technology in the battle against bird flu.
Public health officials have emphasized the importance of Vietnam in the fight against the Asian Bird Flu. What happens in poor, densely populated Vietnam is critical in preventing a global avian flu pandemic.
Experts predict that if the virus mutates into a form that is easily transmitted between humans, and is not contained in Southeast Asia, it could quickly kill up to 7 million people globally.
WHO's Vietnam director Hans Troedsson in news sources has stated, "This is not a Vietnamese problem; this is a global public health problem where Vietnam is on the front line."
"Our first drug, FluCide-I(tm), is now entering internal testing prior to release to external laboratories for animal testing and related work 'said Dr. Anil Diwan, President of NanoViricides, Inc. "I believe that FluCide-I, which is based on the core NanoViricide(tm) technology accompanied by a proprietary ligand that is capable of attachment to Influenza A, Influenza B, and Influenza C virus subtypes, may have a substantially improved effectiveness over the existing drugs. One of the main reasons for our trip to Vietnam will be to create a strategy for developing the ligands that are specific for Bird Flu so that FluCide-I can be quickly redeveloped to be specific against that disease. That resulting new drug will be called AvianFlucide-I(tm)."
FluCide-I is being developed at present as a bronchial aerosol that carries the drug into the bronchial/pulmonary space which is the primary site of infection by influenza viruses.
Eugene Seymour, MD, CEO of NanoViricides, Inc., said, "The enormous threat to the health of the world's population by Bird Flu is finally being acknowledged. Public Health officials are now saying that it is not a question of 'if' but of 'when' the epidemic will explode out of Asia. Tamiflu(tm), a drug produced by Roche Laboratories, is currently the only available treatment. Major governments are now starting to place orders to keep stockpiles of Tamiflu within their borders. The Financial Times reported yesterday that the United States is in talks with Roche to buy a large amount of the drug, and that the contract could be worth $1 billion."
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(tm) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. When a NanoViricide drug enters the patient's blood stream, each nanoscale micelle of the drug attacks and neutralizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus particle by the NanoViricide micelle, destroying it completely. The company plans to develop novel NanoViricide drugs first against HIV and Influenza, and anticipates that it will license the products to major pharmaceutical companies.
This news release was distributed by PrimeZone, www.primezone.com SOURCE: NanoViricides, Inc. NanoViricides, Inc., New York Leo Ehrlich 917-853-6440 leo@nanoviricides.com Anil R. Diwan, Ph.D. adiwan@snet.net
.
Posted by YellowSubmarine on :
News: Nanergy Inc. Issues Manufacturing Order For First Product and Obtains Financing 9/27/2005 7:30:04 AM NEW YORK, Sep 27, 2005 (BUSINESS WIRE) -- Nanergy Inc. ("Nanergy") (OTC Other: NNGY), today announced that it had issued a manufacturing order and provided a letter of credit for its first commercial product, the Nanosign(TM) ever-charged illuminated address sign. Manufactured prototypes are expected within 60 days, and first customer shipments aree expected in January 2006.
Separately, the Company announced that it has entered into private placement agreements in the amount of $300,000, of which $150,000 has been funded and $150,000 is expected to be funded before the end of this month.
About Nanergy Inc.
Nanergy Inc. is a developmental stage company headquartered in New York City, with offices near Princeton, NJ at 4260 Rt 1, Suite 7, Monmouth Junction, NJ 08852as well as in Hungary. Its focus is on developing exciting consumer products that harness nanotechnology, and especially photovoltaic nanofilms, while conducting ongoing research in storing hydrogen using carbon nanotubes. Its new corporate website is still being developed but is available for viewing at http://www.nanergyinc.com.
As Brian Wilson would often say, ..while lounging on the fender of his Beach Buggy.....
I'm staring to get those, "....Good, ...good, ...good --- good vibrations..........
.
Posted by YellowSubmarine on :
NNGY - Official Nanergy Gram:
As Brian Wilson would often say, ..while lounging on the fender of his Beach Buggy..... I'm staring to get those, "....Good, ...good, ...good --- good vibrations..........
.
Posted by Lucas Brachish on :
I had a good run with NNGY earlier, and made a nice chunk of change. But I'm waiting for more confirmed product releases before diving back in... the stock's still quite volatile right now, although there is solid potential for long-term growth if the company keeps moving in this direction ... and investors do love to gobble up anything with the word "nano" in the company title... But for the moment it doesn't seem like the good Dr. Kiss has introduced any really exciting news ... If some more cool products start to come out of the company, or even if some big ideas are announced, and the buzz sparks back up, I'd say NNGY will be a top candidate for both short and long term plays. I haven't done any resaerch on NanoViricides (NNVC) -- they're not connected to NNGY at all, correct? Couldn't help but notice that NNVC PR was posted above, which doesn't seem related ... ? But sounds interesting....
Posted by YellowSubmarine on :
Nanergy Responds to Complaints Regarding Momentum Marketing 10/17/2005 7:30:01 AM
NEW YORK, Oct 17, 2005 (BUSINESS WIRE) -- Nanergy Inc. ("Nanergy") (OTC Other: NNGY), announced today that it has been receiving complaints from recipients of faxes that were purportedly disseminated by Momentum Marketing. The fax purports to describe Nanergy's business and predicts future performance of the Company's stock.
Management of the Company unequivocally disclaims authorship of the fax. The Company has no relationship with Momentum Marketing and has not authorized anyone to provide any such information to the public. The Company is actively and vigorously investigating this matter and is consulting with counsel to determine what legal actions and recourse are available to it to prevent renegade entities from engaging in further unauthorized and unsanctioned activities.
About Nanergy Inc.
Nanergy Inc. is a developmental stage company headquartered in New York City, with offices near Princeton, NJ at 4260 Rt 1, Suite 7, Monmouth Junction, NJ 08852 as well as in Hungary. Its focus is on developing exciting consumer products that harness nanotechnology, and especially photovoltaic nanofilms, while conducting ongoing research in storing hydrogen using carbon nanotubes. Its new corporate website is still being developed but is available for viewing at http://www.nanergyinc.com.
SOURCE: Nanergy Inc. DeMonte Associates Cynthia DeMonte, 212-605-0525 cdemonte*aol.com .
Posted by YellowSubmarine on :
NNVC 0.33 +0.10 (+43.48%) 0 0 1,376,794
I guess a vaccine and cure for the Bird Flu is becoming more attractive.....